




















httpThe Vascular Research Initiatives Conference and
over 25 years of conversations on the science of
vascular disease
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Lexington, Ky; and New Haven and West Haven, ConnThe Vascular Research Initiatives Conference (VRIC) is
an annual conference established in 1986. This conference
has successfully provided a forum for the presentation and
discussion of high-quality innovative and relevant research
related to the scientiﬁc underpinnings of vascular surgery.
We have accomplished this by bringing young and more
accomplished vascular surgeon researchers together with
a broad representation of other high-caliber vascular
biologists. The VRIC provides a unique venue for the
vascular surgery community to showcase research produced
by vascular surgeon scientists—a group of physicians with an
exceptional understanding of vascular disease whose direct
access to patients facilitates acquisition of tissue specimens.
The VRIC creates important interdisciplinary collaborations
among a wide variety of vascular biology investigators.
Goal-directed research progress in vascular biology is crit-
ical, as vascular disease continues to affect much of the
world’s population and, in particular, continues to be the
leading cause of morbidity and mortality for the citizens
of the United States.
The ﬁrst aim of the VRIC is to provide a scientiﬁc
forum for the presentation, dissemination, and critique of
new data regarding preclinical translational research in
vascular surgical diseases. There is emphasis on mechanistic
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patients. This aim is accomplished by (1) selection of the
highest-quality research for a program designed to stimu-
late constructive interaction between all attendees, (2) invi-
tation of a keynote speaker with distinction in the ﬁeld of
vascular research, (3) planned free time for informal discus-
sions and creation of collaborations, and (4) coordinated
and collaborative meeting arrangements with the annual
meeting of the Arteriosclerosis, Thrombosis and Vascular
Biology (ATVB) Council of the American Heart Associa-
tion (AHA), another well-established premier vascular bio-
logy meeting.
The second aim of the VRIC is to provide scientiﬁc and
career development support for aspiring vascular surgeon
scientists. This is provided through (1) presentationsby junior
investigators, coupled with vibrant, thought-provoking,
question-and-answer sessions; (2) opportunities for informal
interactionswith senior faculty and presenters; (3) opportuni-
ties to develop networks with vascular scientists at other
institutes; (4) encouragement of attendance of a broad
community of researchers and appropriate role models,
including women, minorities, and persons with disabilities;
and (5) interaction with representatives from the National
Heart, Lung, and Blood Institute.
Over 100 participants from academia, government, and
industry attend each year. The main strength of the VRIC
is the opportunity for vascular surgeons and biologists to
discuss cutting-edge research in a well-structured, yet
informal and intellectually stimulating atmosphere. This is
expected to stimulate collaborations and new directions
of vascular research, inspired by highly focused, cross-
disciplinary interactions among the conference participants.
The VRIC has an original and innovative format that plays
an essential role in exposing the participants, and especially
junior investigators, to new areas in the important transla-
tional ﬁeld of vascular disease.
CONFERENCE PLAN
Meeting objectives. The VRIC, known formerly as
the Research Initiatives in Vascular Disease Conference,
is an annual conference established in 1986.1,2 This
conference was originally designed to highlight the best
quality and newest vascular surgery research by bringing
the most important vascular surgeon researchers together501
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conference, vascular surgery research has grown in scope as
well as in its ability to perform innovative translational
research.3 However, vascular disease continues to affect
much of the world’s population, and, in particular, it
continues to be the leading cause of morbidity and
mortality for the citizens of the United States.4 The need
for basic and translational research in vascular disease and
vascular surgery remains pivotal to the advancement of our
understanding of vascular pathobiology.
The format of the VRIC has changed only a little since
its inception, other than the changing of the timing and
location of the conference, starting in 2009, to coincide
with the day before the annual spring ATVB Scientiﬁc
Sessions. The structure of the current conference, as
noted earlier, has two main objectives: (1) to provide
a scientiﬁc forum for the presentation, dissemination,
and critique of new data regarding preclinical translational
research in vascular surgical diseases with emphasis on the
study of mechanisms and discovery of novel treatment
targets that may lead to practical applications and treat-
ment of affected patients; and (2) to provide scientiﬁc
and career development support for aspiring vascular sur-
geon scientists.
Logistical arrangements. The VRIC has traditionally
been planned by the Society for Vascular Surgery (SVS)
Research and Education (R&E) committee. The R&E
committee was formed in 1986 with the mission to support
the career development of young research-oriented
vascular surgeons.2 The chair of the committee (Table) is
usually a 3-year position and that leads an eight- to 10-
person committee. The SVS R&E committee is respon-
sible for planning of the VRIC. This planning involves
many tasks, including program structure, abstract review,
program selection, and selection of the invited speakers.
The SVS R&E committee receives advice and oversight
from the SVS Research Council. The chair of the SVS
Research Council and the chair of the R&E committee
regularly discuss plans for the VRIC throughout the year,
both formally during monthly conference calls and infor-
mally as needed.
From its inception in 1986 until 2008, the VRIC was
held in the Washington, DC area. The original intention
of choosing this location was to encourage attendance by
the staff of the National Institutes of Health (NIH).
However, in 2009, the location and time of the meeting
were changed to occur on the day preceding the ATVB
Scientiﬁc Sessions. This change has been highly successful
in facilitating exchange between the vascular surgery and
vascular biology communities. The particular goals are
(1) to promote scientiﬁc exchange and collaboration
between vascular surgeons and vascular biologists, (2) to
provide increased exposure to the VRIC program, and
(3) to promote ever increasing cooperation and scientiﬁc
interaction between the two conferences while maintaining
a focus on issues critical to vascular surgery.
The 2009 meeting took place on April 28, 2009, in
Washington, DC. Although this was the ﬁrst VRICmeetingthat was tied to theATVBmeeting, themeetingwas success-
ful by all accounts, including the attendance and the quality
of the scientiﬁc presentations. The 2010 VRIC, held on
April 7, 2010, in San Francisco, California, capitalized on
the momentum of the 2009 meeting. Vascular surgeons
and vascular biologists both commented, in postmeeting
evaluations, that the coordination of the meeting with
ATVB was “outstanding” and “promoted interactions” as
well as “promoted future collaborations.” The quality of
the science was noted to be “outstanding” and “under
recognized by the broader community,” suggesting the
need to continue the combined new format (Fig 1). The
2011 VRICwas held on April 27, 2011, in Chicago, Illinois,
andwas viewed as similarly outstanding as the 2010meeting,
building on the efforts of the previous year and advancing
both science as well as collaboration between the vascular
surgery and vascular biology communities (Fig 2). Dr Dar-
dik and Dr Lentz, chair of the ATVB Scientiﬁc Sessions
Program Committee, made a video describing the success
of the VRIC and ATVB meetings’ integration and collabo-
ration (available on YouTube at: http://www.youtube.
com/watch?v¼6TfuJ8-zlBU; as well as the SVS and AHA
conference websites). Similarly, Dr Dardik and Dr Mary
McDermott, Chair of the AHA Peripheral Vascular Disease
Council, made a video during the 2012 conference (avail-
able on YouTube at: http://www.youtube.com/watch?
v¼PH_2WA-Wr4s; and at the respective conference
websites).
Program format. The VRIC is organized around
several core themes that are decided upon by the program
committee. Each core topic consists of several abstract pre-
sentations. An invited speaker or panel begins the morning
and afternoon sessions. Invited speakers are senior distin-
guished investigators of international reputation, chosen by
the program committee and approved by the chair of the
committee. The program committee chooses the panels.
Abstracts are chosen by the program committee from the
highest-scoring abstracts that were submitted in response to
the “Call for Abstracts” for the meeting. Abstracts are scored
in blinded fashion by the program committee.
Between each core session, time is allotted for interac-
tion. Breakfast, lunch, and postsession reception time are
scheduled to promote interaction and discussion. Based
upon feedback from the 2009 meeting, the lunch speaker
was eliminated in favor of small group discussion. The feed-
back from the 2010 and 2011 meetings suggested that this
change was quite favorable. Based on feedback from the
2011 meeting, an after-lunch panel session on translational
research was added to the 2012 meeting.
Before the start of the ﬁrst session are the introductory
remarks of the program chair as well as the reports of the
previous year’s K08 and K23 awardees. The SVS promotes
the NIH K08 and K23 grant programs for its trainees and
junior faculty members, with the highest-scoring awardees
receiving matching funding. This program has been
extremely successful, with all awardees ﬁnishing this
program achieving the status of an independent investi-
gator.5 Over 20 K08 and K23 awards have been given.2
Fig 1. Total number of attendees at the Vascular Research
Initiatives Conference (VRIC) from 2007 to 2012. The associa-
tion with the American Heart Association’s Arteriosclerosis,
Thrombosis and Vascular Biology (ATVB) Scientiﬁc Sessions
began in 2009, and we have seen consistent growth in participa-
tion since that time.
Fig 2. Results of the evaluations of the scientiﬁc program by
attendees of the Vascular Research Initiatives Conference (VRIC)
from 2007 through 2011. The scale for evaluation ranges from 1
(poor) to 5 (excellent). The attendees were asked to evaluate the
program relevance and overall quality each year. This period
encompasses the period of change in format and location, and
demonstrates that the mean evaluation scores have been consis-
tently very good to excellent.
Table. The Vascular Research Initiatives Conference (VRIC), 1986-2012
Year Conference title Organizer
1986 Workshop on Vascular Disease Eugene Strandness, MD
1988 Research Initiatives Conference Eugene Strandness, MD
1989 Intimal Hyperplasia Frank W. LoGerfo, MD
1990 Thrombosis And Thrombolysis Frank W. LoGerfo, MD
1991 Prosthetic Arterial Grafts Frank W. LoGerfo, MD
1992 Molecular Biology And Vascular Surgery G. Patrick Clagett, MD
1993 Ischemia, Reperfusion And Organ Dysfunction G. Patrick Clagett, MD
1994 Research Models in Vascular Disease and Symposium on Transluminally Placed Endovascular
Prostheses
G. Patrick Clagett, MD
1995 Atherosclerosis and Restenosis: The Failure of Conventional Wisdom Alexander W. Clowes, MD
1996 Vascular Gene Transfer: Models of Disease and Therapy Alexander W. Clowes, MD
1997 How to Build a Blood Vessel Alexander W. Clowes, MD
1998 Inﬂammatory and Immune Mechanisms in Vascular Disease Howard P. Greisler, MD
1999 Movers and Shakers in the Vascular Tree—Hemodynamic and Biomechanical Factors in Blood
Vessel Pathology
Howard P. Greisler, MD
2000 The Biology of Vascular Interventions—Minimally Invasive Approaches to Vascular Disease Howard P. Greisler, MD
2001 Cellular Signaling—Pathways for the Development of Vascular Disease K. Craig Kent, MD
2002 From Bench to Clinical Practice—Translational Research in Vascular Disease K. Craig Kent, MD
2003 Emerging Technology and the Future of Vascular Research K. Craig Kent, MD
2004 From Bench to Bedside to Boardroom Robert W. Thompson, MD
2005 Translational Research on Vascular Diseases: The Road Ahead Robert W. Thompson, MD
2006 Tools for the Next Decade Robert W. Thompson, MD
2007 Inﬂammation and Thrombosis—Mechanisms and Prevention Larry W. Kraiss, MD
2008 Clinical Trials in Vascular Disease: Getting Answers That Matter Larry W. Kraiss, MD
2009 Research Initiatives in Vascular Disease Conference Larry W. Kraiss, MD
2010 Toward Better Models of Vascular Disease Alan Dardik, MD, PhD
2011 Basic Foundations of Translational Research in Vascular Disease Alan Dardik, MD, PhD
2012 Experimental and Applied Vascular Biology Alan Dardik, MD, PhD
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ﬁrst funded year of research are presented at the VRIC.
The VRIC sessions are planned to occur on the day
immediately after the ATVB Scientiﬁc Sessions. This allows
VRIC attendees to attend the ATVB conference as well
as ATVB conference attendees to attend the VRIC confer-
ence. Several of the ATVB conference sessions are plannedin coordinate fashion between the SVS and ATVB program
committees, including the ﬁrst day combined morning
session as well as the evening poster session of the ATVB
conference. This integration of VRIC with ATVB is
a distinct advantage of VRIC compared with other surgical
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Surgical Conference, which are stand-alone meetings and
not planned coordinately with a basic science partner.
Problems to be addressed. The program reﬂects the
state-of-the-art basic science research performed in
vascular surgery. As such, the breadth of vascular surgery is
represented. Typical topics include peripheral arterial
disease, both acute and chronic; ischemia/reperfusion;
vascular endothelium; thrombosis; aneurysms; angiogen-
esis; stem cells; diabetes and metabolism; bioengineering;
tissue engineering; animal models. Other topics may be
included as needed.
Meeting audience. As noted, the attendance for the
meeting is growing and currently has an audience of
approximately 100 participants. Participants include vas-
cular surgeons, vascular biologists, members of industry,
NIH administrators and scientists, and others, including
scientists or clinicians in related disciplines. The meeting
is advertised in several places, including paper and online
versions of vascular surgery journals and websites, the
VRIC website, and the ATVB Scientiﬁc Sessions website.
Blast e-mails are sent to the members of the SVS. Next
year the abstract selection will be expanded to the members
of the AHA ATVB Council. The VRIC is the only annual
vascular surgery meeting devoted to discussion, presenta-
tion, and dissemination of basic science research. The
ATVB Scientiﬁc Sessions has some overlapping content
and is often attended by similar participants; this was
precisely the rationale that led the leaders of both the
SVS and ATVB to suggest coordination of the annual
VRIC and ATVB meetings. However, the separate identity
of the VRIC, even if it is coordinated with the ATVB
meeting, is critical to its recognition as the premier vascular
surgery scientiﬁc meeting.
VRIC 2012
The Organizing (Program) Committee (2011-
2012). The committee consisted of Alan Dardik, Yale
University (chair); April Boyd, University of Manitoba;
Ankur Chandra, University of Rochester (candidate
member); John Curci, Washington University; Matthew
Eagleton, Cleveland Clinic; Raul Guzman, Vanderbilt
University; Peter Henke, University of Michigan; Christo-
pher Owens, University of California San Francisco; Ravi
Veeraswamy, Emory University; and Omaida Velazquez,
University of Miami.
The program. The 2012 VRIC program is an excellent
example of the high-quality programs brought together
annually. It showcased the top-notch vascular research
being performed by surgeons and other investigators
worldwide. Authors and attendees were a diverse group
that included investigators from the United Kingdom,
Netherlands, Canada, Australia, Israel, France, Switzerland,
and the United States. All sessions were co-moderated by
a scientiﬁc member of the SVS and ATVB.
The program consisted of two invited speakers span-
ning a spectrum of experience and a four-speaker panel
selected to present the opportunities and challenges oftranslational vascular research. However, the heart of the
meeting was the scientiﬁc sessions, which included new
and exciting research on the common topics of intimal
hyperplasia (IH; number of presentations ¼ 5), angiogen-
esis/arteriogenesis (5), ischemic myopathy (2), abdominal
aortic aneurysms (AAAs; 8), deep venous thrombosis/
endothelial dysfunction (3), diabetic wound healing (2),
carotid plaque instability (1), and tissue-engineered grafts
(2) as well as novel fully synthetic vascular endografts (1).
INVITED SPEAKERS
A staple of the annual program is a talk from a recent
career development awardee in vascular surgery; this talk
is eagerly awaited each year. This year’s presentation was
from the most recent Vascular Surgeon NIH K23 program
awardee, Dr Brian Nolan, of the Dartmouth-Hitchcock
Medical Center. Dr Nolan described his planned work to
evaluate the effects of a diagnosis of a small AAA on the
quality of life of patients who undergo a surveillance
regimen. He described a rigorous scientiﬁc plan to evaluate
a large cohort of patients with small AAA at multiple insti-
tutions across the country. He also described his plan for
career development, which included speciﬁc training in
psychometrics that will allow him to continue to contribute
to the critically important evaluation of quality-of-life
results for patients with vascular disease.
The keynote speaker for the VRIC Senior Investigator
Invited Lecturer was Dr Michael T. Watkins, of Harvard
Medical School and the Massachusetts General Hospital.
His talk was titled “Translational Research in Spinal Cord
Ischemia-Reperfusion Injury.” His talk emphasized the
limitations of animal models and the importance of devel-
oping animal models that are closely congruent with
human disease.
SCIENTIFIC PRESENTATIONS
These sessions were lively and included thought-
provoking questions from the moderators and the at-
tendees. Moderators for each session consisted of a team
of two scientists, one from the SVS R&E committee and
one from the ATVB Scientiﬁc Sessions program committee.
The moderators this year were Raul Guzman, MD, from
Vanderbilt University Medical Center; Katey Rayner,
PhD, from NYU Langone Medical Center; Peter Henke,
MD, from University of Michigan; William Muller, MD,
PhD, from Northwestern University; Matthew Eagleton,
MD, from Cleveland Clinic; Robert Hegele, MD, from
University of Western Ontario; Ankur Chandra, MD,
from University of Rochester; and David A. Dicheck, MD,
from University of Washington.
Intimal hyperplasia. An interesting clinical study was
presented from the University of Florida, where ﬂuid shear
from lower extremity bypass grafts were computed by
duplex ultrasound and computed tomographic scanning
in 33 patients early and late after implantation, along
with evaluation of serum markers of inﬂammation. Areas
of low shear at 1 week were reported to be associated
with development of graft stenosis, which was more
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inﬂammation.
Potential mechanisms of IH development were re-
ported from the University of Wisconsin-Madison and
the University of Maryland. The Wisconsin investigators
presented a series of experimental results that implicated
the activity of protein kinase Cd and macrophage chemoat-
tractant protein-1 in the migration of smooth muscle cells
(SMCs) into the diseased intima. The Maryland investiga-
tors found that MARCKS signaling is increased in vein
grafts and that inhibition of this signaling speciﬁcally blocks
proliferation of vascular SMCs and may work through cell
cycle modulating protein p27kip1.
Presentations from Northwestern University and the
University of Tennessee addressed issues surrounding
potential local therapies to reduce IH. The effect of nitric
oxide on inhibition of IH in the setting of diabeteswas found
to be related to proteins responsible for ubiquination and
degradation of intracellular peptides by the Northwestern
group. The Tennessee group evaluated the effectiveness of
gene transfer in blocking expression of membrane-type 1
matrix metalloproteinase (MMP) with a polymeric transfec-
tion method and found that it appeared to be as effective as
prior methods of transfection.
Angiogenesis/arteriogenesis. The mechanisms that
result in the development of perfusion conduits to an
ischemic extremity and the means to enhance angiogen-
esis/arteriogenesis were the focus of ﬁve presentations.
The ﬁrst of these from Pittsburgh evaluated the purogenic
receptor P2Y2 on the arteriogenic response to hindlimb
ischemia in mice and found that absence of the P2Y2
receptor impaired the development of arteries after ischemic
challenge.
The remainder of the presentations evaluated the poten-
tial for stem cell therapy to enhance the response to ischemia.
Blood markers of endothelial damage and active stem cell
mobilization were found to be increased in patients with
critical limb ischemia in a large clinical trial from the
Netherlands. These investigators also demonstrated evi-
dence of impaired production and function of circulating
angiogenic stem cells in this population.
The presentation from a group in Indiana suggested that
progenitor cell treatment using cells derived from the cho-
rionic villi of human placenta are better than adipose-
derived stem cells for promoting angiogenesis after ischemia.
From Massachusetts, we had two reports regarding
endothelial progenitor cell function in diabetics. One
group of investigators reported that oxidative stress in dia-
betic stem cells, mediated through Nox4, can reduce the
angiogenic potential of these cells. They also presented
evidence that inhibition of Nox4 can restore the angiogenic
properties of the cells. The other group evaluated the effect
of p53 silencing on stem cells obtained from diabetic mice,
which were infused into ischemic limbs, and found better
angiogenic response with these cells compared with cells
without p53 silencing.
Ischemic myopathy. Understanding the changes in
muscle subjected to ischemia was another focus of theresearch. An investigative team from London and
Switzerland as well as researchers from Pittsburgh pre-
sented study results regarding the mechanisms of ischemic
changes in muscle. Both groups looked at the Toll-like
receptor (TLR) pathway, and both groups independently
presented evidence that muscle necrosis in response to
ischemia is related to the MyD88 downstream signaling
from TLR activation.
Abdominal aortic aneurysms. The effect of cytokines
on AAA development was featured by several groups.
Investigators from Virginia and Indiana presented results
of studies involving the role of interleukin (IL)-17 in the
development of aneurysm disease. They demonstrated
that IL-17 is increased in human tissue and that the
absence of the protein in a mouse model results in smaller
aneurysms with reduced production of interferon-g and
tumor necrosis factor-a. Another group of investigators
from Virginia demonstrated the presence of increased IL-
1b in human AAA and that deﬁciency of both IL-1b and
the IL-1 receptor inhibits the development of AAA in
a mouse model.
Cellular immunity was also evaluated in AAA. A group
from France presented work regarding the effect of regula-
tory (CD4þCD25þ) cells on the development and rupture
of model aneurysms. Although neither Th1 nor Th2
lymphocyte inhibition affected aneurysm development in
this model, the investigators showed evidence that Treg
cell depletion increased aneurysm severity and the inci-
dence of aortic rupture. Investigators from Stanford sug-
gested that splenocyte trafﬁcking may play a role in some
models of AAA development, particularly as a reservoir
for inﬁltrating monocytes.
Molecular pathways that may affect the phenotype
or growth of SMCs were evaluated by researchers from
Townsville, Australia, and Rochester, New York. The
Australian group presented data implicating increased
urocortin-2 as a mechanism for the poor growth of
aneurysm-derived SMCs. The Rochester group presented
data implicating reduced sonic hedgehog and Notch
signaling in the growth inhibition and phenotypic changes
characteristic of cells from AAA.
Investigators from Massachusetts, Israel, and Maryland
applied leptin-containing gels to the aorta of apolipopro-
tein E–deﬁcient animals. These experiments resulted in
enhanced AAA formation suggesting that leptin may play
a role in AAA development.
Finally, computational models were used by a group
from Winnipeg, Canada to evaluate the stress and shear
characteristics of the aorta to develop predictive modeling
of aortic rupture.
Deep venous thrombosis/endothelial dysfunction.
Two groups investigated the unique features of the pulmo-
nary endothelium on both local and remote disease. An
investigator group from Rochester evaluated differences
in pulmonary and peripheral endothelium reactivity and
ﬁbrinolytic activity to help understand the occurrence of
pulmonary embolism in a patient without deep venous
thrombosis. Another group from Houston explored the
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injury and presented evidence that apoptosis of pulmonary
endotheliummay be related to tumor necrosis factor-a release
due to ischemic renal injury.
Researchers from Michigan evaluated the regulation of
MMP and its relationship to thrombus resolution in an
acute model of deep venous thrombosis. By evaluating
the changes in this model in response to plasminogen acti-
vator inhibitor-1 deﬁciency, the evidence suggested that
MMP-9 and MMP-2 were suppressed despite an increase
in ﬁbrinolytic activity.
Diabetic wound healing. Understanding the mecha-
nisms related to poor wound healing in diabetics was evalu-
ated by two research groups. A group fromMiami presented
data on improved response of diabetic wound healing to
stromal cell derived factor-1 a when it is used to stimulate
bone marrow cells before injection into the wound. Inves-
tigators from Michigan looked at bone marrow cells from
diabetics and found evidence for epigenetic changes to the
cells that promote an M1 macrophage phenotype.
Carotid plaque instability. A clinical study was
undertaken by a research group from New Orleans to eval-
uate changes that may result in vulnerable carotid athero-
sclerotic plaque. They reported that the microribonucleic
acid miR-221 was signiﬁcantly decreased in the plaque of
patients presenting for urgent carotid endarterectomy.
Tissue engineered grafts. The research into the devel-
opment of vascular conduits from biologics continues to
progress as highlighted in two presentations. Investigators
from Pennsylvania and New Jersey evaluated the differenti-
ation potential of stem cells from diabetic patients and pre-
sented results suggesting that these cells can form a lining on
a vascular graft. Researchers from Connecticut evaluated
the mechanical and histologic properties of bioengineered
grafts used for venous reconstruction and found important
differences in these properties compared with normal vein.
Synthetic vascular endografts. A group of investiga-
tors from London and Oxford in the United Kingdom
described the development and characteristics of a nano-
composite polymer stent graft for use in proximal aortic
disease. They presented new evidence that this novel poly-
mer has compliance characteristics that more closely mimic
normal vascular compliance compared with other stan-
dard graft materials (expanded polytetraﬂuoroethylene and
Dacron).
TRANSLATIONAL RESEARCH PANEL
As a new item for the conference, the program also
included a panel of senior investigators who presented talks
and ﬁelded questions regarding practical issues in convert-
ing research ﬁndings in the laboratory into practical treat-
ments for patients. The ﬁrst talk by Dr Michael Conte of
the University of San Francisco discussed a number of
important issues regarding the translation of a concept
for a novel pharmacotherapeutic into humans. The talk
included drug development costs and the available public
funding mechanisms available to investigators with an
idea. He gave a helpful description of differences betweenSmall Business InnovationResearch (SBIR) and Small Tech-
nology Transfer Innovation Research (STTR) programs at
the NIH, as well as the Science Moving towArds Research
Translation and Therapy (SMARTT) program, which
provides services to investigators to support regulatory
submissions and preclinical studies, manufacturing, preclin-
ical study planning, and pharmacology/toxicology services.
Finally, he discussed the recent Vascular Interventions/
Innovations and Therapeutic Advances (VITA) program
from the National Heart, Lung, and Blood Institute, which
speciﬁcally focuses on translational support for treatments of
noncardiac vascular disorders, thrombotic diseases, and
pulmonary hypertension.
The second talk by Dr Christopher Breuer of Yale
University School of Medicine focused on unique aspects
of bringing a bioengineered tissue product to clinical trial.
He emphasized some of the unique regulatory hurdles to
performing studies in the United States. Based on his expe-
riences, Dr Breuer noted the importance of reassessing the
results of interventions in the clinic and bringing those
observations back to the laboratory in order to develop
an improved product.
From the Mayo Clinic, Dr Peter Gloviczki, the current
President of the SVS, described his career in research and
presented some of the components of the framework for
a successful program of research in an individual career
and as part of an academic program. With regard to research
program development, he discussed the need for a stimula-
tory environment and for selecting staff surgeons with
research interest and providing them with sufﬁcient oppor-
tunity to develop their research program (50% minimum
time). He noted that leaders should be involved and thereby
lead by example. He similarly emphasized for the individual
investigator the need to be part of cooperative groups of
investigators, including basic scientists and other clinicians,
to create a multidisciplinary team. He also emphasized
the importance of sharing responsibility and recognition
among the team.
The current chair of the Research Council of the SVS,
Dr Larry Kraiss of the University of Utah, discussed the
speciﬁc support mechanisms and research goals of the
Society. Current available funding mechanisms through
the SVS were presented and discussed. Key awards include
the supplemental support for early-stage vascular surgeon
researchers who receive Mentored Clinical Scientist Devel-
opment Awards from the National Heart, Lung, and Blood
Institute. He noted the success of the program where 12 of
16 recipients in the K08 pathway have gone on to receive
funding through R01 or equivalent VA award mechanisms.
Dr Kraiss described how clinical/translational studies
are also supported through three mechanisms. One is the
Clinical Research Seed Grant, which provides funding of
up to $15,000 for a 1-year project by an SVS member or
a board-eligible vascular surgeon under the mentorship of
an SVS member. He also presented a recently introduced
funding mechanism patterned broadly after the NIH
R34, the “Multicenter Clinical Studies Planning Grant,”
which will provide $100,000 for 1 year to support the
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and other mechanics necessary to establish a study to
answer an important clinical question in a multicenter trial
format. The ﬁnal mechanism pertains to large clinical trials.
The SVS will evaluate the protocols and may award a letter
of approval from the President of the SVS to be used to
signify support of the trial to funding and other agencies.
Lastly, Dr Kraiss reported that the SVS has committed
funds to nurture the next generation of clinical investiga-
tors through support of students doing research in labora-
tories mentored by members of the SVS.
THE IMPACT AND FUTURE OF THE VRIC
Its original organizer, Dr Eugene Strandness, reﬂecting
upon the VRIC after its ﬁrst 10 years, elegantly summa-
rized the contributions of the VRIC to the science of
vascular surgery:
“.one must fairly ask to what extent this collaborative
effort has been a success. It is my view that it has succeeded
in many different ways. First, and perhaps most impor-
tantly, it has provided a forum for an interchange of ideas
and in-depth discussion of important problems. In addi-
tion, because it is held annually, most topics that are dis-
cussed are timely and up-to-date. Both the NIH and the
scientiﬁc community have beneﬁted from this type of
exposure.. As one will note from the programs over the
years, the topics reviewed at the meetings have been of
increasing complexity. This is in a sense a mirror of what
is happening in real life. In addition, these conferences
do provide a forum for ‘science,’ which is often put aside
these days because of our concerns over health care delivery
and cost containment. Although there is no argument over
concerns related to health care delivery, the solutions to
many of our problems in the future will come from the
basic science community. It is my view that the leader-
ship.should be commended for urging this kind of collab-
orative effort.”1
Some of the practical successes of the VRIC meeting
were subsequently reviewed a decade later.2,5 In particular,
this meeting has stimulated a generation of vascular
surgeon–scientists. At this point, over 20 NIH K awards
have been awarded to vascular surgeons, all of which
have been presented at VRIC. The meeting has stimulated
numerous young vascular surgeons to enter research
careers. It has helped develop collaborations focused on
solving speciﬁc issues in vascular surgery research.
As evidenced by the presentations at the 2012
meeting, the ability of the VRIC to provide an essential
forum for communication and collaboration for the solu-
tions of the future remains strong. The VRIC is the only
meeting devoted to discussing and presenting the basic
and translational science related to the broad discipline
of vascular surgery. As such, this meeting is a unique
opportunity for vascular surgeons who perform basic and
translational research, as it is (1) the only annual venuedevoted to state-of-the-art basic science research in the
ﬁeld of vascular surgery, (2) the only annual venue devoted
to vascular surgeons presenting basic science research to
their peers, (3) the only annual venue for vascular surgery
trainees to present their work to their peers, (4) the only
annual venue for vascular surgeons and vascular biologists
to review vascular surgery basic science research, and (5)
the most visible venue for NIH/SVS K08/K23 awardees
to present their research. These awards represent the ﬁrst
partnership of NIH with a surgical society for K08 grant
sponsorship.2
The progress of the past several years is anticipated to
continue to impact the prominence of the VRIC. Main-
taining and growing the conference through outreach to
international scientiﬁc contributors as well as the ﬂourish-
ing of the collaboration with the ATVB will continue to
yield signiﬁcant value for the meeting attendees. Ulti-
mately, the VRIC will continue to play an important role
in the scientiﬁc process and will provide an environment
conducive to the development of important discoveries to
improve the health of all patients with vascular disease.
The next conference is scheduled to take place at the
Dolphin Hotel, Orlando, Fla, on April 30, 2013.
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